Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in HR+, HER2- recurrent or metastatic breast cancer (MONARCH plus)
NCT02763566Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of abemaciclib in Hormone-Receptor-Positive Breast Cancer, sponsored by Eli Lilly and Company. Started Dec 2016; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT02763566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02763566.